As Chief Scientific Officer for Clear Labs, I lead the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, I prioritize team culture and empower my team members to maximize their talents and push the bounds of what’s possible. As a scientist and researcher, I have deep insights into the world of health, biotechnology, and next-generation sequencing, and I continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. I want to leave a legacy by raising the quality of life and health of the world’s population. Through my work at Clear Labs, we have made a huge impact on food safety. I aim to expand that impact by using my skills to improve clinical and pharmaceutical genomics and their effectiveness in public health.
Sequencing technologies Showcase:
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity.
Automated pathogen-agnostic isolate Whole Genome Sequencing
Overcoming barriers to genomic hospital infection control requires sample-to-insight automation with low time-to-results.
In his current role, Nicholas Gallerani, Ph.D., focuses on scientific communication and collaboration related to the applications and performance of NuProbe’s molecular technologies. Prior to joining NuProbe, he was a Fellow at Columbia Technology Ventures, where he assessed new technologies generated by Columbia University research labs. Nick received his Ph.D. in Pathobiology and Molecular Medicine from Columbia University and has co-authored four scientific publications.
Sequencing Tech Showcase:
NuProbe takes a multi-platform approach to apply breakthrough technologies in genomics research to enable diseases to be detected, treated, and cured at early stages for better outcomes with lower costs.
Emerging solutions for non-invasive cancer monitoring
Learn how NuProbe's proprietary technology addresses current limitations in liquid biopsy
Shawn has over 20 years of experience in genomic applications development and technology optimization, as well as operational management of research, development, and clinical testing programs. Prior to joining Element, Shawn was Chief Scientific Officer at Discovery Life Sciences and a faculty investigator at the HudsonAlpha Institute for Biotechnology. While at HudsonAlpha, Shawn developed a comprehensive genomics facility that has supported more than 5,200 projects from locations around the world. His laboratory raised more than $150M in extramural funding, culminating in the largest financial transaction in HudsonAlphas history when the assets of his research group were sold to Discovery Life Sciences. Before HudsonAlpha, Shawn was a faculty member at Vanderbilt University Medical Center in the Department of Biomedical Informatics and the Department of Molecular Physiology and Biophysics. He is an author or coauthor of more than 200 peerreviewed publications with over 45,000 citations.
Sequencing technologies Showcase:
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. For our first product AVITI is a modular and high-performing DNA sequencing platform that will deliver high-quality data, workflow flexibility and make next-generation sequencing technology more accessible.
Democratizing and decentralizing DNA sequencing with the Element
The AVITI system flips the script by providing higher quality data at a much lower cost.